In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • Sincere thanks to Cancer Commons and their Virtual Tumor Board for their comprehensive analysis and recommendations regarding treatments for my pancreatic cancer. I feel fortunate to have the benefit of the expertise offered by their board of scientists, researchers, physicians, and experts in this field.

    Roy Saenz

  • Emma has been so helpful and kind to my wife.

    Husband of cancer patient

  • Cancer Commons is extremely engaged and proactive. Its professionals have directed us towards interesting avenues to explore in our search for additional treatment options.

    Mark Bezner
    Husband of stage IV ovarian cancer patient

  • The team at Cancer Commons provided options above and beyond what the local care team had offered. Such a great service for patients.

    Anonymous

  • I appreciated the quick response after my registration with Cancer Commons. The nurse navigator was prompt and compassionate. I knew my request wasn’t going to be buried and didn’t have time to wonder how long it would take before I got a response. The scientist Lauren connected me too was very prompt in giving me answers to my question. And when I asked questions... Read more »

    Gail Lung cancer patient

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.